Associated Papers
Tumor mutational burden modulates the prognostic effect of RAS mutations in metastatic colon cancer: mechanistic insights and genotype-phenotype correlations.
Ianniello M et al.
Journal of Translational Medicine, 2025
Molecular characterisation of Mozambican patients diagnosed with colorectal adenocarcinoma.
Selemane C et al.
Journal of Gastrointestinal Oncology, 2025
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
Indeterminate DC histiocytosis is distinct from LCH and often associated with other hematopoietic neoplasms.
Ozkaya N et al.
Blood Advances, 2024
Use of 3' Rapid Amplification of cDNA Ends (3' RACE)-Based Targeted RNA Sequencing for Profiling of Druggable Genetic Alterations in Urothelial Carcinomas.
Mitiushkina NV et al.
International Journal of Molecular Sciences, 2024
Exploring the Relationship Between KRAS, NRAS, and BRAF Mutations and Clinical Characteristics in Iranian Colorectal Cancer Patients.
Mosaferi Z et al.
Journal of Gastrointestinal Cancer, 2024
Histological evidence of MAPK pathway activation across subtypes of adult orbital xanthogranulomatous disease irrespective of the detection of oncogenic mutations.
Detiger SE et al.
Clinical Immunology (orlando, Fla.), 2024
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways.
Mondal K et al.
Cells, 2024
Dynamics of RAS Mutations in Liquid Biopsies in Metastatic Colorectal Cancer Patients-Case Series and Literature Review.
Popescu I et al.
Journal of Personalized Medicine, 2024
Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy.
Osumi H et al.
Nature Communications, 2024
A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer.
Osumi H et al.
Translational Oncology, 2023
Clinical, Pathological and Molecular Insights on KRAS, NRAS, BRAF, PIK3CA and TP53 Mutations in Metastatic Colorectal Cancer Patients from Northeastern Romania.
Afrăsânie VA et al.
International Journal of Molecular Sciences, 2023
Completion of Genetic Testing and Incidence of Pathogenic Germline Mutation among Patients with Early-Onset Colorectal Cancer: A Single Institution Analysis.
Storandt MH et al.
Cancers, 2023
Performance Characteristics of Oncomine Focus Assay for Theranostic Analysis of Solid Tumors, A (21-Months) Real-Life Study.
Bamba-Funck J et al.
Diagnostics (basel, Switzerland), 2023
Mutations in Classical Signaling Pathways and Their Functional Impact in Microsatellite Instability High Colorectal Cancer.
Shi S et al.
Genetic Testing and Molecular Biomarkers, 2023
Case Report: Longitudinal monitoring of clonal evolution by circulating tumor DNA for resistance to anti-EGFR antibody in a case of metastatic colorectal cancer.
Sagawa T et al.
Frontiers in Oncology, 2023
Rare presentation of multiple thromboses in Erdheim-Chester disease: a case-based review.
Liu Y et al.
International Journal of Hematology, 2022
Circulating Tumor DNA: Less Invasive, More Representative Method to Unveil the Genomic Landscape of Newly Diagnosed Multiple Myeloma Than Bone Marrow Aspirates.
Liu Y et al.
Cancers, 2022
Performance of Idylla™ RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer.
Makutani Y et al.
International Journal of Clinical Oncology, 2022
HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature.
Mathiot L et al.
Current Oncology (toronto, Ont.), 2022
Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use.
Chevrier S et al.
International Journal of Molecular Medicine, 2022
Utility of Select Gene Mutation Detection in Tumors by the Idylla Rapid Multiplex PCR Platform in Comparison to Next-Generation Sequencing.
Nkosi D et al.
Genes, 2022
A saturation-mutagenesis analysis of the interplay between stability and activation in Ras.
Hidalgo F et al.
Elife, 2022
Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer.
Lavacchi D et al.
Frontiers in Oncology, 2022
C677T and A1298C MTHFR gene polymorphisms and response to fluoropyrimidine-based chemotherapy in Mestizo patients with metastatic colorectal cancer.
Ramos-Esquivel A et al.
Pharmacogenetics and Genomics, 2021
Concordance of acquired mutations between metastatic lesions and liquid biopsy in metastatic colorectal cancer.
Taniguchi F et al.
Future Science Oa, 2021
BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer.
Ohnami S et al.
Molecular and Cellular Biochemistry, 2021
Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer.
Loree JM et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2021
Clinicopathological characteristics and mutational profile of KRAS and NRAS in Tunisian patients with sporadic colorectal cancer
Ounissi D et al.
Turkish Journal of Medical Sciences, 2021
KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples.
Loong HH et al.
Translational Lung Cancer Research, 2020
Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma.
Manzoni M et al.
Cancers, 2020
The extended spectrum of RAS-MAPK pathway mutations in colorectal cancer.
Costigan DC et al.
Genes, Chromosomes & Cancer, 2020
Positive Correlation Between Somatic Mutations in RAS Gene and Colorectal Cancer in Telangana Population: Hospital-Based Study in a Cosmopolitan City.
Goud KI et al.
Applied Biochemistry and Biotechnology, 2020
Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance.
Schwartzberg LS et al.
Npj Precision Oncology, 2020
Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer.
Lazzari L et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2019
Mutation profiling of cancer drivers in Brazilian colorectal cancer.
Dos Santos W et al.
Scientific Reports, 2019
Genotyping of Circulating Tumor DNA Reveals the Clinically Actionable Mutation Landscape of Advanced Colorectal Cancer.
Cao W et al.
Molecular Cancer Therapeutics, 2019
KRAS and NRAS pyrosequencing screening in Tunisian colorectal cancer patients in 2015.
Jouini R et al.
Heliyon, 2019
Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer.
Osumi H et al.
Cancer Medicine, 2019
Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study.
Taniguchi H et al.
Neoplasia (new York, N.y.), 2018
Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study.
Udar N et al.
Journal of Cancer Research and Clinical Oncology, 2018
Spatio-temporal tumor heterogeneity in metastatic CRC tumors: a mutational-based approach.
Del Carmen S et al.
Oncotarget, 2018
Rapid Somatic Mutation Testing in Colorectal Cancer by Use of a Fully Automated System and Single-Use Cartridge: A Comparison with Next-Generation Sequencing.
Al-Turkmani MR et al.
The Journal of Applied Laboratory Medicine, 2018
Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition.
Yamazaki K et al.
Cancer Science, 2018
Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue.
Johnston L et al.
Journal of Clinical Pathology, 2018
Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in Melanoma.
Barel F et al.
Acta Dermato-venereologica, 2018
Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas.
Sadlecki P et al.
Disease Markers, 2018